Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma

Idarubicin, a new analogue of daunorubicin, was administered p.o. for 3 consecutive days every 3 weeks at a dose of 45 mg/m2 in 46 patients (45 eligible and evaluable) with previously treated, favorable histology, non-Hodgkin's lymphoma. Median clinical characteristics included an age of 66 yea...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 50; no. 21; pp. 6833 - 6835
Main Authors CASE, D. C, HAYES, D. M, GERBER, M, GAMS, R, ERVIN, T. J, DORSK, B. M
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.11.1990
Subjects
Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Drug Evaluation
Humans
Idarubicin - administration & dosage
Idarubicin - therapeutic use
Idarubicin - toxicity
Lymphoma, Non-Hodgkin - drug therapy
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Antineoplastic agent
Therapeutic efficiency
Human
Chemotherapy
Toxicity
Phase II trial
Oral administration
Anthracyclins
Malignant hemopathy
Malignant tumor
Non Hodgkin lymphoma
Route of administration
Online AccessGet full text

Cover

More Information
Summary:Idarubicin, a new analogue of daunorubicin, was administered p.o. for 3 consecutive days every 3 weeks at a dose of 45 mg/m2 in 46 patients (45 eligible and evaluable) with previously treated, favorable histology, non-Hodgkin's lymphoma. Median clinical characteristics included an age of 66 years, a performance status of 1, and one prior chemotherapeutic regimen. Forty-one patients were relapsing from prior therapy, and 37 had stage IV disease. Patients with prior anthracycline therapy were excluded. Responses were observed in 58% of patients (10 complete and 16 partial), with a median duration of 6+ months (2-41+ months). Idarubicin was well tolerated. Nonhematological toxicities (nausea/vomiting, mucositis/diarrhea, alopecia, and anorexia) were observed in less than or equal to 50% of patients. Median hematological values during the first cycle include a WBC of 4100/mm3 and a platelet count of 147,000/mm3. With dose escalation, hematological toxicity was the dose-limiting toxicity. Symptomatic cardiac toxicity was not observed. Median values for the resting left ventricular ejection fraction during the course of therapy were 0.65 (initial) and 0.63 (final). Idarubicin in oral form is an active drug in previously treated patients with favorable histology non-Hodgkin's lymphoma.
ISSN:0008-5472
1538-7445